Group 232.png

News & Events

Vector 27.png

Pinpoint Science Receives NIH RADx Funding to Advance a 30-Second High-Sensitivity Covid-19 Antigen

October, 2020

We are thrilled to be working with the NIH RADx Next team to accelerate our groundbreaking SARS-CoV-2 nanosensor antigen test.  

 

The RADx initiative provides world-class clinical, technical, commercialization, regulatory support, and expert one-on-one guidance to project teams, in addition to funding for solutions like Pinpoint Science’s SARS-CoV-2 Nanosensor antigen test.